Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective

Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective

Accumulating clinical evidence shows that psychedelic therapy, by synergistically combining psychopharmacology and psychological support, offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and/or maladaptive habitual patterns of emotion, cognition and beha...

Full description

Bibliographic Details
Main Authors:	John R. Kelly, Claire M. Gillan, Jack Prenderville, Clare Kelly, Andrew Harkin, Gerard Clarke, Veronica O'Keane
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-12-01
Series:	Frontiers in Psychiatry
Subjects:	psychedelics hallucinogens psilocybin research domain criteria (RDoC) lysergic acid diethylamide (LSD) dimethyltryptamine (DMT)
Online Access:	https://www.frontiersin.org/articles/10.3389/fpsyt.2021.800072/full

Similar Items

Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review
by: Gniewko Więckiewicz, et al.
Published: (2021-08-01)

Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice
by: Kenneth Alper, et al.
Published: (2023-01-01)

Revisiting the seven pillars of RDoC
by: Sarah E. Morris, et al.
Published: (2022-06-01)

Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample
by: Tor-Morten Kvam, et al.
Published: (2023-11-01)

Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans
by: Francisco Madrid-Gambin, et al.
Published: (2023-12-01)

Application of the RDoC Framework to Predict Alcohol Use and Suicidal Thoughts and Behaviors among Early Adolescents in the Adolescent Brain and Cognitive Development (ABCD) Study
by: Laika D. Aguinaldo, et al.
Published: (2022-07-01)

The Importance of Sensory Processing in Mental Health: A Proposed Addition to the Research Domain Criteria (RDoC) and Suggestions for RDoC 2.0
by: Laura A. Harrison, et al.
Published: (2019-02-01)

RDoC: integration or separation of neuroscience and psychopathology?
by: R. V. Akhapkin
Published: (2019-12-01)

LSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice
by: Kenneth Alper, et al.
Published: (2018-08-01)

Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials
by: Juan José Fuentes, et al.
Published: (2020-01-01)

A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder
by: Mario Renato Velit-Salazar, et al.
Published: (2024-03-01)

A Response to: "A Commentary on "Stabilizing Constructs through Collaboration across Different Research Fields as a Way to Foster the Integrative Approach of the Research Domain Criteria (RDoC) Project"
by: Jacqueline Anne Sullivan
Published: (2016-08-01)

Use of a Self-Regulation Failure Framework and the NIMH Research Domain Criterion (RDoC) to Understand the Problem of Procrastination
by: Idit Shalev
Published: (2018-05-01)

Scoping Review: The Role of Psychedelics in the Management of Chronic Pain
by: Robinson CL, et al.
Published: (2024-03-01)

Acute Lysergic Acid Diethylamide Does Not Influence Reward-Driven Decision Making of C57BL/6 Mice in the Iowa Gambling Task
by: Lauri V. Elsilä, et al.
Published: (2020-12-01)

Drugs in therapy. LSD, MDMA, marijuana, psilocybin, designer drugs and its potential in modern medicine.
by: Agata Tadeja
Published: (2020-09-01)

Commentary: Stabilizing constructs through collaboration across different research fields as a way to foster the integrative approach of the Research Domain Criteria (RDoC) project
by: Walter Glannon
Published: (2016-07-01)

Effects of Ayahuasca on Personality: Results of Two Randomized, Placebo-Controlled Trials in Healthy Volunteers
by: Juliana Mendes Rocha, et al.
Published: (2021-08-01)

An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)
by: Carina Joy Donegan, et al.
Published: (2023-10-01)

Acute effects of lysergic acid diethylamide (LSD) on resting brain function
by: Felix Müller, et al.
Published: (2019-09-01)

Suicidal cut‐throat wound during LSD intoxication
by: Palash Kumar Bose, et al.
Published: (2021-11-01)

Pengalaman Anak Jalanan Usia Remaja Dalam Perilaku Inhalasi Lysergic Acid Diethylamide
by: Chatarina Suryaningsih, et al.
Published: (2019-10-01)

A disorder in executive functions crosses traditional diagnostic borders of the schizophrenia-bipolar spectrum
by: I. Szendi Md Habil, et al.
Published: (2022-06-01)

Editorial: Biotyping in Psychiatry
by: Tae Young Lee, et al.
Published: (2022-02-01)

Cornu Ammonis Changes Are at the Core of Hippocampal Pathology in Depression
by: Darren Roddy, et al.
Published: (2019-05-01)

Editorial: Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders
by: Grace Blest-Hopley, et al.
Published: (2023-05-01)

N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function
by: Steven A. Barker
Published: (2018-08-01)

The Research Domain Criteria framework: transitioning from dimensional systems to integrating neuroscience and psychopathology
by: Samet Kose, et al.
Published: (2017-01-01)

posttraumatic stress disorder: a theoretical model of the hyperarousal subtype
by: Charles Stewart Weston
Published: (2014-04-01)

A 5-min paradigm to evoke robust emotional reactivity in neuroimaging studies
by: Dean Sabatinelli, et al.
Published: (2023-03-01)

Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?
by: N. Descalço, et al.
Published: (2021-04-01)

Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial
by: Robin J. Murphy, et al.
Published: (2024-02-01)

Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs
by: Zurina Hassan, et al.
Published: (2017-08-01)

Enhanced Vigilance Stability during Daytime in Insomnia Disorder
by: Ariane Losert, et al.
Published: (2020-11-01)

Modeling the normal:abnormal spectrum of early childhood internalizing behaviors: A clinical‐developmental approach for the Multidimensional Assessment Profiles Internalizing Dimensions
by: Lauren S. Wakschlag, et al.
Published: (2023-11-01)

Onset of psychiatric signs and impaired neurocognitive domains in inherited metabolic disorders: A case series
by: François Medjkane, et al.
Published: (2021-03-01)

Integrating DSM/ICD, Research Domain Criteria, and Descriptive Psychopathology in Teaching and Practice of Psychiatry
by: Dimy Fluyau
Published: (2018-10-01)

PAM trial protocol: a randomised feasibility study of psychedelic microdosing–assisted meaning-centred psychotherapy in advanced stage cancer patients
by: Alesha Wells, et al.
Published: (2024-02-01)

Understanding the effects of lysergic acid diethylamide and the importance of its prevention
by: Burak Okumuş, et al.
Published: (2023-09-01)

Mini-review: The neurobiology of treating substance use disorders with classical psychedelics
by: Marvin M. Urban, et al.
Published: (2023-04-01)